Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 881Neoplasms 668Prostatic Neoplasms 455Lung Neoplasms 368Colorectal Neoplasms 335Carcinoma, Non-Small-Cell Lung 320Leukemia, Myeloid, Acute 257Pancreatic Neoplasms 224Brain Neoplasms 210Multiple Myeloma 204Neoplasm Metastasis 201Carcinoma, Hepatocellular 184Head and Neck Neoplasms 183Glioblastoma 170Precursor Cell Lymphoblastic Leukemia-Lymphoma 169Melanoma 159Ovarian Neoplasms 158Squamous Cell Carcinoma of Head and Neck 152Recurrence 139Rectal Neoplasms 137Hematologic Neoplasms 130Sarcoma 126Uterine Cervical Neoplasms 124Stomach Neoplasms 118Carcinoma, Renal Cell 118Triple Negative Breast Neoplasms 116Glioma 116Motor Activity 105Urinary Bladder Neoplasms 100Myelodysplastic Syndromes 99

Interventions

mirdametinib 1Everolimus 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Lymphangioma × 90 days × Clear all
NCT05983159 2026-05-05

TARGET-VM

Murdoch Childrens Research Institute

Phase 2 Recruiting
50 enrolled

Arteriovenous Malformations, Lymphangioma, Skin Diseases, Vascular, Lymphangioma, Cystic, Lymphatic Abnormalities, Vascular Malformations

NCT07477548 2026-03-17

A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies

Yonsei University

Phase 2 Not yet recruiting
67 enrolled

Arteriovenous Malformations, Hemangioendothelioma, Hemangioma, Lymphangioma, Nevus, Vascular Malformations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡